CYC Shares Cyclopharm Limited
ASX · ASXLast in our picks 2026-10-14 — not in the current list; analysis below is from that screen
Specialized medical imaging growth and product adoption provide niche healthcare upside.
Signal breakdown
- ▸Niche imaging exposure supported by product commercialization potential.
- ▾Below 50-day MA (-8.08%)
- ▾Near 52-week low (1.8% of range)
Is CYC a buy right now?
Trend: CYC is trading below the 50-day average (-23.40%), RSI 36 — neutral momentum, with a 3-month return of -38.46%.
Valuation & quality: Cyclopharm Limited trades on forward P/E -4.0, price-to-book 1.42; fundamentals show net margin -53.2%, return on equity -53.9%, revenue growth 13.6% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$1.02 (+183.4% vs the last close; range A$1.02 – A$1.02), consensus rating “none”.
Our screen: WATCH (score 0) — Specialized medical imaging growth and product adoption provide niche healthcare upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -3.50% | -11.00% | -2.70% | -33.80% | +23.40% | -5.20% | -16.40% | -21.70% |
Fundamentals
Analyst price target
Technical signals
About Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally.
Sector: Healthcare · Industry: Medical Devices · Australia · 104 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.